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Abstract: Metastatic disease is responsible for most of cancer lethality. A main obstacle for therapy of advanced cancers 
is that the outcome of metastasis depends on a complex interplay between malignant and host cells. The perioperative pe-
riod represents an underutilized window of opportunity for cancer treatment where tumor-host interactions can be modu-
lated, reducing the risk of local recurrences and distant metastases. Blood-saving agents are attractive compounds to be 
administered during tumor surgery. Desmopressin (DDAVP) is a safe and convenient hemostatic peptide with proved an-
timetastastic properties in experimental models and veterinary clinical trials. The compound seems to induce a dual an-
giostatic and antimetastatic effect, breaking the cooperative function of cancer cells and endothelial cells during residual 
tumor progression. DDAVP is therefore an interesting lead compound to develop novel synthetic peptide analogs with en-
hanced antitumor properties. 
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INTRODUCTION 
  Metastasis is formed when a cell, or a group of cells, 
leaves the original site of the primary tumor and establishes a 
new colony in a distant site. To form an overt metastasis 
tumor cells must overcome the physical, physiological and 
immunological constraints imposed by the tissue milieu and 
initiate invasive growth [1]. Traditionally, cancer progres-
sion is viewed as a complex multi-step process, where tumor 
cells gradually acquire the capacity to invade and intravasate 
into the systemic circulation or the lymphatic system. How-
ever, successful colonization at distant organs depends on the 
ability of circulating tumor cells to survive in the blood 
stream, to leave circulation by extravasation and then to 
adapt to the new microenvironment [2]. 
  Metastatic disease is responsible for most of cancer le-
thality, therefore understanding the intricate interplay be-
tween tumor cells, soluble factors, extracellular matrix 
(ECM) and host cells during cancer spread is crucial to de-
sign successful therapeutic interventions. Emerging evidence 
indicates that disseminated tumor cells are present in the 
circulation in large numbers even at early stages of cancer, 
before metastatic foci at distant organs can be detected [3]. 
Furthermore, it has been suggested that solid tumor surgery 
can promote tumor growth, and also facilitate metastatic 
dispersal and distant growth [4]. In addition, a recent discov-
ery suggests that circulating tumor cells are able to reinfil-
trate tumors at their primary organs and promote tumor pro-
gression [5]. This intriguing phenomenon of “tumor-self 
seeding” provides new insights into the dynamics of tumor 
progression. Each metastatic site may serve as a nesting 
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ground to generate tumor variants that repopulate other me-
tastatic sites as well as the primary tumor [6]. 
BIOLOGY OF TUMOR INVASION AND METASTA-
SIS 
  Tumor invasion can be classically divided into three se-
quential steps: adhesion of tumor cells to the basement 
membrane and ECM, disruption of matrices by proteolytic 
digestion, and migration through the digested barrier [7]. 
Adhesion of tumor cells to the basement membrane involves 
specific anchoring glycoproteins, such as fibronectin, 
laminin and collagens, which bind to a variety of tumor cell 
surface receptors. To penetrate the ECM, invading cells must 
disrupt local segments in the organized structure of the 
basement membrane, a tightly regulated process involving 
proteolytic enzymes [8]. Metastatic capacity also depends on 
angiogenesis, a process by which the tumor induces the for-
mation of new blood vessels, beginning with capillary buds 
and progressing to a vascular network. Metastasis requires 
active cell motility, not only for the endothelial cells during 
angiogenesis but also for the tumor cells. The collective mi-
gration of cells as a cohesive group is a hallmark of the tis-
sue remodelling events during embryogenesis, wound repair 
and cancer invasion. Migratory cells move as sheets, strands 
or clusters rather than individually, and use similar actin- and 
myosin-mediated protrusions and guidance by extrinsic 
chemotactic and mechanical cues as used by single cells [9]. 
The newly formed blood vessels within and around the tu-
mor mass provide nutrients for tumor growth, and also create 
an easy access to circulation for metastatic spread [10]. In-
terestingly, a biological similitude between tumor invasion 
and angiogenesis underlines a cooperative function of cancer 
cells and endothelial cells during tumor progression. 
  Although a large number of cancer cells can be released 
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survive to produce metastatic tumors [11]. This so-called 
“metastatic inefficiency” has been well-documented in ex-
perimental animal models. As a result of interactions with 
the microvasculature at the target organ, some malignant 
cells are eliminated instantly by mechanical trauma where 
others are killed relatively slowly, over minutes or hours, by 
the inflammatory and immune responses [12, 13]. 
  Metastatic cells entering into the blood stream possess 
the capacity to interact with all components of the hemostatic 
system, such as platelets, effectors of coagulation and fibri-
nolysis, leukocytes and the vascular endothelium. These in-
teractions may determine the formation of microthrombi that 
increase the efficiency of the metastatic cascade [14]. Semi-
nal experimental studies demonstrated that fibrin deposition 
enhances intravascular tumor cell aggregation and trapping 
in the target organ, and also protects circulating cells from 
destruction by host immunity [15]. In the last years research 
studies have greatly improved our knowledge on the com-
plex bidirectional relationship of cancer and hemostasis. Un-
derstanding the molecular basis of the underlying mecha-
nisms may help to pharmacologically modulate the hemo-
static properties of malignant cells to interfere with the pro-
gression of the disease [14, 16]. 
THE PERIOPERATIVE “WINDOW OF OPPORTU-
NITY” 
  Excisional surgery is the primary treatment modality for 
solid cancers. However, many common epithelial cancers 
carry a poor prognosis even after curative resection of early 
stage tumors. Tumor progression in these cases has been 
attributed to the persistence of occult neoplastic cells in vari-
ous body compartments, as a sign of minimal residual dis-
ease (MRD). Regrettably, little is known about the condi-
tions required for the persistence of micrometastatic dor-
mancy or the escape from the dormant phase into the active 
phase of metastasis formation [17]. There is increasing evi-
dence indicating that tumor removal alters the growth of 
MRD, leading to perioperative tumor growth. Mechanisms 
by which surgery could promote tumor growth and worsen 
prognosis include direct seeding of tumor at local sites, tu-
mor manipulation, stimulation of subclinical tumor by 
postsurgical inflammation, and accelerated metastatic tumor 
growth due to loss of inhibitory factors derived from the 
primary tumor [4]. Distant metastases are kept in a dormant 
state by antiangiogenic mediators produced by the main tu-
mor mass. Preclinical studies have shown that surgical exci-
sion of the primary cancer reactivates growth of metastasis 
[18, 19]. Furthermore, the inflammatory process associated 
with surgery shares mediators with tumor growth and inva-
sion. Macrophages, fibroblasts and humoral factors of in-
flammation have been shown to enhance tumor growth in 
preclinical models [19, 20]. 
 Coffey  et al. have proposed a novel therapeutic para-
digm, that the perioperative period “represents a window of 
opportunity during which the patient may be further pro-
tected against the oncological effects of tumor removal” 
[21]. Because neoplasia is a systemic disease, this concept 
may be relevant to all patients undergoing surgery for can-
cer. In the same line, Van der Bij et al. have recently ana-
lyzed the underlying mechanisms in colorectal cancer sur-
gery and concluded that “perioperative therapeutic window 
of opportunity offers promising means of improving patient 
outcome, but is unfortunately underutilized” [22]. Surgical 
removal of the primary tumor provides the best chance of 
long-term disease-free survival for patients with solid can-
cers but, paradoxically, surgery itself contributes to the de-
velopment of both local recurrences and distant metastases. 
  It has been suggested that surgical manipulation can pro-
voke liberation of viable cancer cells. The presence of ma-
lignant cells in the peripheral blood has been confirmed by 
RT-PCR in patients undergoing breast cancer surgery [23]. 
Similarly, conventional chemotherapy may cause a mobiliz-
ing effect on breast cancer cells [24]. An immunohisto-
chemical study on the pattern of sentinel lymph node metas-
tasis in breast cancer suggested that the frequency of positive 
nodes is increased after instrumentation of the tumor site 
[25]. Other authors reported the histological findings in a 
series of axillary lymph node dissections taken approxi-
mately two weeks after breast biopsy. They described the 
presence of epithelial cells in the subcapsular sinus of drain-
ing lymph nodes that may be attributed to mechanical trans-
port of tumor breast epithelium secondary to the previous 
needle or surgical manipulation [26]. It was also reported 
that surgical trauma can promote metastasis in gastrointesti-
nal cancers. Esophageal cancer operation resulted in a sig-
nificant increase of circulating tumor cells, as measured in 
blood samples by quantitative RT-PCR, resulting in further 
development of metastasis [27]. Many studies in colorectal 
cancer patients undergoing colonoscopy or endoscopic inser-
tion of colonic stents demonstrated that mechanical forces 
cause liberation of cancer cells [28, 29]. 
  Surgical trauma and concomitant wound-healing proc-
esses induce local and systemic changes, including impair-
ment of tissue integrity and production of inflammatory me-
diators and angiogenic factors [22]. High concentrations of 
proangiogenic factors were detected in surgical wound fluid 
samples from breast cancer patients, suggesting that they 
may need to be antagonized using perioperative systemic or 
local therapy [30]. In this context, local and distant recur-
rence of breast
 cancer may be because of the perioperative 
stimulation of residual
 cancer cells [31]. Besides, surgery can 
lead to immune suppression that may predispose to tumor 
growth and spread [32]. 
  A perioperative treatment may offer the opportunity to 
modulate the early wound environment and reduce locore-
gional cancer recurrence rates. Moreover, enhanced coagula-
tion after tumor manipulation may contribute to a rapid en-
capsulation of residual tumor tissue, limiting intravasation of 
tumor cells. As shown in Table 1, blood-saving agents, such 
as tranexamic acid [33], aprotinin [34] and desmopressin 
(DDAVP) [35], have been used during surgery. Perioperative 
and postoperative administration of the antifibrinolytic agent 
tranexamic acid reduced the frequency of wound complica-
tions in women with breast cancer undergoing lumpectomy 
or mastectomy [33]. Intraoperative infusion of the hemo-
static agent aprotinin, a non-specific protease inhibitor, was 
associated with a significant survival benefit in patients who 
underwent liver resection for colorectal cancer metastasis 
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THE VASOPRESSIN ANALOG DDAVP 
  DDAVP (1-deamino-8-D-arginine vasopressin) is a syn-
thetic analog of the antidiuretic hormone vasopressin, firstly 
described by Zaoral and coworkers in 1967 [36]. The peptide 
sequence of vasopressin includes 9 aminoacid residues, hav-
ing a disulfide bridge between positions 1 and 6. The substi-
tution of L-arginine for D-arginine in position 8 drastically 
reduces the pressor effect of DDAVP and cysteine deamina-
tion in position 1 prolongs its half-life and the other biologi-
cal effects, as shown in Fig. (1). In contrast to vasopressin, 
which binds to different cell membrane receptors (V1a, 
V1b/V3 and V2), DDAVP is a selective agonist for the V2 
membrane receptor [37]. This vasopressin receptor subtype 
is expressed in the kidney collecting duct, mediating the an-
tidiuretic action, and is also present in endothelial cells, me-
diating most of the non-renal effects of DDAVP, including a 
potent hemostatic effect [35, 38]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Peptide sequence of vasopressin. The synthetic analog 
DDAVP differs from the natural peptide by deamination of cystein 
in position 1 (arrowhead), which prolongs its half-life, and D-
arginine substitution in position 8 (arrow), which reduces the pres-
sor effect and confers selectivity for the V2 membrane receptor. 
 
  DDAVP was initially used for antidiuretic replacement 
therapy in the management of diabetes insipidus and enure-
sis. Additionally, DDAVP is a well-tolerated and convenient 
hemostatic compound that can be used during surgery in a 
number of clinical conditions with bleeding diathesis [35]. It 
has several effects on the hemostatic and fibrinolytic system, 
causing release of von Willebrand factor (VWF), coagulation 
factor VIII and tissue-type plasminogen activator (tPA) from 
microvascular endothelial stores. VWF is a large glycopro-
tein playing a role in primary hemostasis, by mediating ad-
hesion of platelets to the subendothelium. VWF is synthe-
sized in endothelial cells and megakaryocytes, and stored as 
a multimer in specialized secretory granules named Weibel-
Palade bodies [38, 39]. DDAVP-induced VWF secretion 
results from V2 receptor-mediated, cAMP-dependent exocy-
tosis. 
  The presence of vasopressin receptors was reported in 
transformed epithelial cells, and also documented in several 
tumor variants, including breast and lung malignancies [40]. 
As indicated by North et al., vasopressin gene-related ex-
pression is a feature of all breast cancers, and products of 
this expression are attractive as potential targets for therapy 
[41]. In addition, neuropeptide receptor expression was de-
tected in a wide panel of human tumor cell lines [42]. 
  DDAVP exhibited modest but significant antiprolifera-
tive effects on MCF-7 and Skbr3 V2 receptor-expressing 
human breast carcinoma cell lines [43, 44]. Such action was 
clearly mediated through agonist V2 receptor signaling, and 
thus involved activation of adenylate cyclase followed by 
intracellular cAMP elevation. The anti-mitogenic effect 
could be blocked by the selective V2 receptor antagonist 
SR121463 [43]. It was also reported that the natural hormone 
vasopressin inhibited the in vitro growth of MCF-7 human 
breast carcinoma cells at high concentrations [45]. 
  Years ago, we have reported that DDAVP can modulate 
both cell growth and secretion of the serine protease 
urokinase in cultures of mouse mammary tumor cells [46]. 
More recently, preliminary results indicated that treatment of 
MCF-7 monolayers with DDAVP, in the presence of proper 
concentrations of plasminogen, induced the formation of 
angiostatin, a natural, tumor-born inhibitor of angiogenesis 
[47]. Since angiostatin is an internal fragment of plasmino-
gen [48], it is likely that DDAVP induces a V2 receptor-
dependent proteolytic processing leading to angiostatin for-
mation. 
ANTIMETASTATIC EFFECTS OF DDAVP 
  We communicated for the first time that intravenous ad-
ministration of DDAVP can impair development of distant 
metastasis. DDAVP, at doses of 1-2 μg/kg, inhibited by 70% 
the experimental lung colonization of aggressive mammary 
cancer cells [49] and dramatically decreased lymph node and 
Table 1   Blood-Saving Agents Used During Cancer Surgery 
Compound  Mechanisms of Action  Type of Agent 
Tranexamic acid  Inhibitor of the conversion of plasminogen to 
plasmin 
Antifibrinolytic agent 
Aprotinin  Non-specific serine protease inhibitor  Antifibrinolytic agent 
DDAVP  Specific agonist of V2 vasopressin receptor on 
endothelial and tumor cells  
Hemostatic and mild cytostatic agent Perioperative Treatment of Metastasis  Current Pharmaceutical Biotechnology, 2011, Vol. 12, No. 11    1977 
distant metastasis in a mouse model of breast tumor manipu-
lation and surgical excision [50]. We ruled out that DDAVP 
induces direct cytotoxicity on tumor cells in such animal 
model, indicating a complex biological mechanism underly-
ing the antimetastatic properties of the compound. Antime-
tastatic resistance was obtained without overt toxic effects in 
mice [50]. 
  Considering the antimetastatic properties of DDAVP, as 
well as its well known hemostatic effect and safety, the com-
pound could be an excellent candidate for adjuvant therapy 
to breast tumor surgery. We conducted a pilot veterinary 
clinical trial in surgically treated bitches with locally-
advanced mammary cancer [51]. DDAVP was administered 
in 2 doses, the first 30 minutes before and the second 24 
hours after surgery, at a clinically-relevant hemostatic dose 
for dogs (1 μg/kg). Perioperative treatment significantly pro-
longed survival, having a beneficial effect both on disease-
free interval and on overall survival. DDAVP appeared to be 
safe at this dose in canine cancer patients and decreased in-
traoperative bleeding [51]. An extended veterinary clinical 
trial recently confirmed these results, showing a particular 
survival benefit in patients with more aggressive carcinoma 
[52]. 
  In comparison with other blood-saving agents such as 
tranexamic acid or aprotinin which display a nonspecific 
antifibrinolytic activity [33, 34], DDAVP seems to exert a 
specific effect on membrane receptors present in both tumor 
and endothelial cells. DDAVP improves perioperative hemo-
stasis and may contribute to encapsulation of residual tumor 
tissue, limiting extravasation of metastatic cells. In mice, 
intravenous DDAVP prevented aggregation of mammary 
carcinoma cells, therefore reducing the efficiency of the me-
tastatic process [49]. As mentioned above, intravenous injec-
tion of DDAVP induces a rapid release of multimeric forms 
of VWF from microvascular endothelial cells, reaching peak 
levels at about 60 minutes and having a plasma half-life of 8-
10 hours [35]. Terraube et al. showed that VWF plays a pro-
tective role against tumor cell dissemination in a mouse 
model [53]. VWF might participate in the interaction of tu-
mor cells with the subendothelium, and appears to obstruct 
metastasis by reducing sustained adherence of malignant 
cells in the microvasculature at the target organ. Further-
more, VWF was shown to directly induce apoptosis of tumor 
cells in vitro and caused death of metastatic cells arrested in 
the lungs [54]. Taking together these observations suggest 
that abrupt release of VWF from the microvasculature may 
favor the collapse of early metastatic foci. Thus, it is likely 
that DDAVP injection not only inhibits perioperative metas-
tatic events but also combats spontaneous micrometastases 
that occurred before surgery. 
PERIOPERATIVE DDAVP IN HUMAN CANCER 
  Although no controlled clinical trials were conducted yet 
in humans to explore the new indication of DDAVP as a 
hemostatic adjuvant during tumor surgery, there are several 
reports that document its satisfactory perioperative use in 
cancer patients [55-59]. Mostly, they referred to patients 
with different hemostatic disorders in whom DDAVP ad-
ministration prevented bleeding during excisional surgery. 
  One of the first reports showed the successful use of 
DDAVP in a woman with von Willebrand disease having an 
ovarian tumor [55]. In another case, a woman of 33 years 
with type II thrombasthenia received DDAVP during the 
resection of a breast tumor diagnosed as fibroadenoma. The 
compound was administered intravenously at a dose of 0.4 
μg/kg, with good tolerance and hemostasis control. Bleeding 
time was reduced from 10 to 4 minutes, platelet adhesion on 
glass was increased from 1.8 to 37% and other hemostatic 
parameters were also increased, such as VWF multimers 
[56]. A patient of 67 years with von Willebrand disease re-
ceived DDAVP during a major thoracic surgery for the re-
section of a lung cancer. Lobectomy and extirpation of 
lymph nodes were carried out and control of hemostasia was 
successful [57]. A more recent work reported the use of 
DDAVP in a patient with type A hemophilia that was sub-
jected to a hepatic resection due to colon cancer metastasis 
[58]. As well, the use of DDAVP has been recommended in 
patients with type A hemophilia subjected to surgery to ex-
cise skin cancer lesions, in order to prevent the peri and 
postoperative bleeding [59]. 
PERSPECTIVES 
  The major cause of death from cancer is due to metastatic 
spread of the disease, existing several factors that account for 
the failure to treat residual metastasis. Perhaps the greatest 
obstacle for therapy of an advanced cancer is that the out-
come of metastasis depends on multiple “cross-talk” interac-
tions of disseminated cells with homeostatic mechanisms 
which the tumor cells usurp [11]. The organ microenviron-
ment can influence the response of metastases to therapy, 
thus treatment of metastasis should be targeted against both 
the malignant cells and critical homeostatic factors that pro-
mote metastasis [2, 11]. In this sense, the perioperative pe-
riod is an attractive window of opportunity to modulate tu-
mor-host interactions, and thus reduce the risk of local recur-
rences and distant metastases. 
  The biological effects of perioperative administration of 
DDAVP on both endothelial and V2 receptor-expressing 
tumor cells are complex, and required further investigations. 
Nevertheless, the peptide seems to induce a dual, reciprocal 
angiostatic and antimetastatic effect, breaking the coopera-
tive function of cancer cells and endothelial cells during tu-
mor progression. As shown in Fig. (2), DDAVP induces a 
tumor-mediated formation of angiostatin, a potent antiangio-
genic effector [47, 50]. At the same time, the compound also 
activates endothelial release of VWF, which in turn obstructs 
biological mechanisms of cancer spread and may cause 
apoptosis of micrometastatic cells arrested in the target organ 
[49, 50, 53, 54]. 
  Thrombosis is a well-recognized complication of cancer, 
particularly in several adenocarcinomas, such as of pancreas, 
that is associated with a higher risk of venous thromboem-
bolism [60]. For most cancers, however, it is not clear to 
what extent major surgery contributes to the thrombotic risk. 
Chemotherapy cycles and the use of erythropoietin, thalido-
mide, high-dose steroids and antiangiogenic therapy increase 
the risk of thrombosis [61]. Although DDAVP is a safe he-
mostatic agent [62], the prothrombotic risk should be care-
fully monitored in patients administered perioperatively with 1978    Current Pharmaceutical Biotechnology, 2011, Vol. 12, No. 11  Alonso et al. 
the compound. DDAVP is an effective blood-saving agent 
for use during surgery in patients with mild hemophilia or 
von Willebrand disease. Antimetastatic properties of 
DDAVP were obtained administering intravenous doses 
within the range previously used to obtain antidiuretic or 
hemostatic effects (0.3-2 μg/kg). These doses have the ad-
vantage of being well characterized from a pharmacological 
point of view [35, 63]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Dual and reciprocal effects of perioperative DDAVP on 
endothelial and tumor cells. Angiostatin is a potent angiostatic ef-
fector and VWF obstructs biological mechanisms of cancer spread 
and may cause apoptosis of micrometastatic foci. 
 
  Peptides such as DDAVP are much appreciated as lead 
compounds for developing human therapeutics to face the 
increased demand of new molecules. Pharmaceutical indus-
tries had rekindled the interest in peptides. Nowadays, more 
than 50 peptides are in the pharmaceutical world market, and 
more than a hundred are in several clinical phases. Peptides 
as active pharmaceutical ingredients show unique features 
(high biological activity, specificity and stability, and low 
toxicity), thereby making those attractive candidates as 
therapeutic agents [64, 65]. Furthermore, small peptides can 
be industrially prepared at rather low cost, which can fit the 
needs of the medical industry. Merrifield solid-phase peptide 
synthesis (SPPS) constitutes a key breakthrough from the 
perspective of accelerating research and discovery, and of its 
widespread application for the manufacture of peptides at the 
industrial scale. More than 50% of the approved peptide 
pharmaceuticals are manufactured using SPPS techniques 
[66]. Currently, a panel of linear and cyclic vasopressin pep-
tide analogs with improved antitumor effects is in develop-
ment in our laboratory [67]. Punctual amino acid substitu-
tions in DDAVP generate novel synthetic oligopeptides with 
enhanced cytostatic, antimetastatic and/or antiantiogenic 
effects, to be tested in preclinical tumor models. 
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ABBREVIATIONS 
cAMP  =  Cyclic adenosine monophosphate 
DDAVP = Desmopressin (1-deamino-8-D-arginine vaso-
pressin) 
ECM =  Extracellular  matrix 
MRD  =  Minimal residual disease 
RT-PCR = Reverse transcription-polymerase chain reac-
tion 
SPSS  =  Solid-phase peptide synthesis  
VWF  =  Von Willebrand factor 
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